Wendy DiCicco

Wendy F.
DiCicco is currently Independent Director at EyePoint, Inc. since 2019, Director at National Association of Corporate Directors (Philadelphia), Director at Imvax, Inc. since 2020, Chief Financial Officer at Genetix Biotherapeutics, Inc. starting 2025, Member of The American Institute of Certified Public Accountants, Member of National Association of Corporate Directors (Virginia), Member of Pennsylvania Institute of Certified Public Accountants, Member of Women Corporate Directors, Member of The CFO Alliance, and Chief Financial Officer at FerGene, Inc. Former roles include Independent Director at Coherent Corp.
from 2011 to 2017, Director at Golden Dragon Holding Co., Independent Director at SynCardia Systems LLC from 2015 to 2016, Independent Director at SWK Holdings Corp.
from 2022 to 2023, Independent Director at CannaPharmaRx, Inc. from 2015 to 2016, Director at Carmell Regen Med Corp.
from 2018 to 2021, Director at Sincerus Pharmaceuticals, Inc. from 2021 to 2022, Director at ExpressCells, Inc., Chief Financial Officer at DSM Biomedical, Inc. from 1996 to 2008, Chief Financial Officer at Globus Medical, Inc. from 2008 to 2009, Chief Financial Officer at Quench USA, Inc. from 2010 to 2011, Chief Financial & Operating Officer at Centinel Spine LLC from 2017 to 2018, Staff Accountant & Senior Accountant at Deloitte & Touche LLP from 1990 to 1996, Manager-Accounting & Audit at Deloitte LLP (New York) in 1996, Member of Financial Executives International, Chief Financial Officer, Treasurer & VP at Nuron Biotech, Inc. from 2012 to 2014, President & Chief Operating Officer at Camber Spine Technologies LLC from 2014 to 2017, Chief Financial Officer at Renovacor, Inc. from 2019 to 2022, Chief Financial Officer at Akari Therapeutics Plc from 2023 to 2024, and Chief Financial Officer at Renovacor Holdings, Inc. from 2019 to 2022.
Education includes undergraduate studies at Thomas Jefferson University.